RSS | Login | Register

NAPRELAN

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare NAPRELAN to:

Generic Name for NAPRELAN

Naproxen (as sodium) 375mg, 500mg, 750mg; controlled rel tabs.

Legal Classification:

Pharmacological Class for NAPRELAN

NSAID (arylacetic acid deriv.).

Manufacturer of NAPRELAN

Victory Pharma

Indications for NAPRELAN

Rheumatoid arthritis. Osteoarthritis. Ankylosing spondylitis. Acute gout. Tendinitis. Bursitis.

Adult dose for NAPRELAN

Rheumatoid arthritis, osteoarthritis, or ankylosing spondylitis: 750mg–1g once daily; max 1.5g once daily. Acute tendonitis or bursitis: 1g once daily, or 1.5g once daily for a limited period; max 1g/day thereafter. Gout: 1–1.5g once daily for 1 day then 1g once daily until attack subsides.

Children's dosing for NAPRELAN

Not recommended.

Contraindications for NAPRELAN

Aspirin allergy. 3^rd trimester pregnancy. Coronary artery bypass graft surgery.

Warnings/Precautions for NAPRELAN

Advanced renal disease: not recommended. Active peptic ulcer. History of GI disease. Impaired renal or hepatic function. Heart failure. Edema. Hypertension. Pre-existing asthma. Bleeding disorders. Monitor blood, ocular, and liver function in chronic use. Discontinue if liver dysfunction occurs. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for NAPRELAN

Avoid aspirin. Serum levels increased by probenecid. May potentiate protein-bound drugs (eg, phenytoin, sulfonylureas, sulfonamides). Monitor oral anticoagulants. May antagonize diuretics, antihypertensives. Increased renal toxicity with ACE inhibitors. Methotrexate excretion reduced. Increases lithium levels. Increased risk of GI bleed with alcohol.

Adverse Reactions for NAPRELAN

GI upset, bleeding, or ulceration; headache, flu syndrome, constipation, abdominal pain, dizziness, paresthesias, insomnia, rash (discontinue if occurs), edema, hyperglycemia, arthralgia, myalgia, renal dysfunction, blood dyscrasias, others. See literature re: risk of cardiovascular events.

How is NAPRELAN supplied?

Tabs 375mg—100
500mg—75
750mg—30
Dose card (10-day therapy)—20 (750mg x 6 tabs + 500mg x 14 tabs)

Related Disease:

Ankylosing spondylitis

Arthritis~NSAIDs

Rheumatoid arthritis

Arava Boxed Warning updated to include severe liver injury

July 13, 2010

The FDA has updated the Boxed Warning of Arava (leflunomide, from sanofi aventis) to highlight the risk of severe liver injury in patients using this drug and how this risk may be reduced.

Phase 3 study of Lodotra for the treatment of rheumatoid arthritis (RA)

June 17, 2010

Horizon Pharma announced that data from its Phase 3 study of Lodotra showed a statistically significant improvement in American College of Rheumatology (ACR) response criteria in patients with rheumatoid arthritis (RA).

Phase 3 trial of Lodotra for rheumatoid arthritis

June 16, 2010

Horizon Pharma announced positive results from its Phase 3 registration study of Lodotra (prednisone tablet), that showed a statistically significant improvement in American College of Rheumatology (ACR) response criteria in patients with rheumatoid arthritis (RA).

FDA accepts NDA for Duexa for ulcer risk reduction in arthritis patients

May 26, 2010

Horizon Pharma announced that its New Drug Application (NDA) for Duexa was accepted by the FDA for the reduction of the risk of development of upper gastrointestinal ulcers in patients with arthritis and pain.

Salonpas Pain Relief Patch and Salonpas Arthritis Pain patch available

May 24, 2010

Hisamitsu announced the launch of Salonpas Pain Relief Patch (10% methyl salicylate and 3% I-menthol) and Salonpas Arthritis Pain patch (10% methyl salicylate and 3% I-menthol) for the temporary relief of mild to moderate aches and pains of the muscles and joints associated with arthritis, sprains, strains, bruises and simple backaches experienced by patients age ≥18 years.